June 16, 2021
The Ministry of Health, Labor and Welfare (MHLW) on June 15 ordered label revisions to add new side effect risks for MSD’s PD-1 inhibitor Keytruda (pembrolizumab) and Eli Lilly’s anti-human IL-17A monoclonal antibody Taltz (ixekizumab). For Keytruda, the new label...read more